The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
REGULATORY LDP Lawmakers’ League on Generics Prods Minister to Rethink Off-Year Revisions
May 29, 2024
-
BUSINESS Cheplapharm to Take Over 2 More Brands from Clinigen in Japan
May 29, 2024
-
BUSINESS Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
-
BUSINESS Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
-
BUSINESS Daiichi Sankyo’s TROP2 ADC Shows OS Benefit in Subgroup of NSCLC
May 28, 2024
-
REGULATORY Health Minister Acknowledges Changes after 2016 Decision on Off-Year Revisions
May 28, 2024
-
BUSINESS Alzheimer’s Med Leqembi Approved in South Korea, Its 4th Market
May 28, 2024
-
REGULATORY MHLW Panel OKs Avigan for SFTS with Strings Attached, Shionogi COVID Jab Only for Primary Use
May 27, 2024
-
BUSINESS Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
May 27, 2024
-
BUSINESS MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
-
BUSINESS Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
-
REGULATORY LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
-
ORGANIZATION JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
-
REGULATORY MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
-
BUSINESS AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
-
BUSINESS Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
-
REGULATORY MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report
May 23, 2024
-
REGULATORY Japan Govt to Launch Public-Private Forum to Attract Investments
May 23, 2024
-
REGULATORY No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
-
BUSINESS AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…